Skip to main content
SpringerLink
Log in

Subchronic Administration of Noopept and Semax Peptides Increases the Density of Cortical GABAA-Receptors in the Brain of BALB/c Mice

  • EXPERIMENTAL ARTICLES
  • Published:
Neurochemical Journal Aims and scope Submit manuscript

Abstract—The effects of noopept (1 mg/kg/day) and semax (0.6 mg/kg/day) on ex vivo [3H]-muscimol binding to GABAA-receptors in the prefrontal cortex of inbred BALB/c and C57BL/6 mice were examined after subchronic intraperitoneal (i.p.) and intranasal (i.n.) administration known to produce nootropic and anxiolytic activity in BALB/c but not in C57BL/6 mice. It was found that the initial specific binding (Bmax) and dissociation constants (Kd) for GABAA-receptors do not differ significantly between the two strains. However, in BALB/c mice i.p. noopept and semax administration increased GABAA-receptor density by 38 and 68% compared to the control group whereas after i.n. administration the increase was by 18 and 37%, respectively, which is in accord with the data on a more pronounced anxiolytic effect of i.p. peptide administration than i.n. administration. However, none of the drugs exerted a significant effect on the characteristics of GABAA-receptors in C57BL/6 mice, except for noopept, which decreased the Bmax value by 20% after i.p. administration. The similarity of noopept and semax effects on the GABAA-receptor density for both administration routes as well as the correlation of these changes with the intensity of anxiolytic effects depending on the administration route may indicate the involvement of GABAA-receptors in the mechanisms underlying the anxiolytic effects of these peptides.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.

Similar content being viewed by others

REFERENCES

  1. Mironov, A.N., The Guidelines for Preclinical and Clinical Studies of Drugs. Part 1, Moscow: Grif i K, 2012.

    Google Scholar 

  2. Kovalev, G.I., Firstova, Yu.Yu., Salimov, R.M., and Kondrakhin, E.A., Psikhiatriya, 2010, vol. 45, no. 3, pp. 23–27.

    Google Scholar 

  3. Vasil’eva, E.V., Salimov, R.M., and Kovalev, G.I., Experimental and Clinical Pharmacology, 2012, vol. 75, no. 7, pp. 32–37.

  4. Kovalev, G.I., Kondrakhin, E.A., Salimov, R.M., and Neznamov, G.G., Experimental and Clinical Pharmacology, 2013, vol. 76, no. 9, pp. 3–10.

  5. Kovalev, G.I., Kondrakhin, E.A., Salimov, R.M., and Neznamov, G.G., Experimental and Clinical Pharmacology, 2014, vol. 77, no. 12, pp. 49–55.

  6. Kovalev, G.I., Firstova, Yu.Yu., and Salimov, R.M., Experimental and Clinical Pharmacology, 2007, vol. 71, no. 12, pp. 12–17.

  7. Kovalev, G.I. and Firstova, Yu.Yu., Klin. Farmakol. Ther., 2010, vol. 19, no. 6, pp. 72–73.

  8. Kovalev, G.I., Vasil’eva, E.V., and Salimov, R.M., Zhurnal VND, 2019, vol. 69, no. 1, pp. 123–130.

    Google Scholar 

  9. Vasileva, E.V., Kondrakhin, E.A., Abdullina, A.A., Salimov, R.M., and Kovalev, G.I., Neurochem. J., 2020, vol. 14, no. 3, pp. 268–278.

    Article  CAS  Google Scholar 

  10. Kondratenko, R.V., Derevyagin, V.I., and Skrebitsky, V.G., Neurisci. Lett., 2010, vol. 476, pp. 70–73.

    Article  CAS  Google Scholar 

  11. Sharonova, I.N., Bukanova, Yu.V., Myasoedov, N.F., and Skrebitskii, V.G., Bull. Exp. Biol. Med., 2018, vol. 164, no. 5, pp. 612–616.

    Article  CAS  Google Scholar 

  12. Haefely, W., Kulcsar, A., and Mohler, H., Psychopharmacol. Bull, 1975, vol. 11, pp. 58–59.

    CAS  PubMed  Google Scholar 

  13. Smith, K.S., Engin, E., Meloni, E.G., and Rudolph, U., Neuropharmacology, 2012, vol. 63, pp. 250–258.

  14. Glowinski, L.L. and Iversen, J., J. Neurochem., 1966, vol. 13, no. 8, pp. 655–669.

  15. Vasil’eva, E.V., Kondrakhin, E.A., Salimov, R.M., and Kovalev, G.I., Experimental and Clinical Pharmacology, 2016, vol. 79, no. 9, pp. 3–11.

  16. Vasil’eva, E.V., Salimov, R.M., and Kovalev, G.I., Farmakokinetika i Farmakodinamika, 2016, no. 2, pp. 31–36.

  17. Ito, Y., Lim, D.K., Hayase, Y., Murakoshi, Y., and Ho, I.K., Neurochemical Research, vol. 17, no. 4, pp. 307–313.

  18. Hawkinson, J., Acosta-Burruel, M., Kimbrough, C.L., Goodnough, D.B., and Wood, P.L., Eur. J. Pharmacol., 1996, vol. 304, nos. 1–3, pp. 141–146.

    Article  CAS  Google Scholar 

  19. Firstova, Yu.Yu., Vasil’eva, E.V., and Kovalev, G.I., Experimental and Clinical Pharmacology, 2010, vol. 74, no. 1, pp. 6–10.

  20. Seredenin, S.B., Voronina, T.A., Neznamov, G.G., Blednov, Yu.A., Badyshtov, B.A., Viglinskaya, I.V., Kozlovskaya, M.M., Kolotilinskaya, N.V., Yarkova, M.A., Savel’ev, V.L., Garibova, T.L., and Val’dman, E.A., Vestn. Ross. Akad. Med. Nauk, 1998, vol. 11, pp. 3–9.

    Google Scholar 

  21. Voronina, T.A. and Seredenin, S.B., Experimental and Clinical Pharmacology, 2002, vol. 65, no. 5, pp. 4–17.

  22. Rudolph, U. and Mohler, H., ARPTDI, 2004, vol. 44, pp. 475–498.

    CAS  PubMed  Google Scholar 

Download references

Funding

The study was performed as part of State Assignment no. 0521-2019-0009 “Analyzing receptor mechanisms and searching for CNS protection drugs in cerebrovascular and cognitive disorders.”

Author information

Authors and Affiliations

  1. Zakusov Institute of Pharmacology, Russian Academy of Sciences, ul. Baltiiskaya 8, 125315, Moscow, Russia

    E. V. Vasil’eva, A. A. Abdullina & G. I. Kovalev

Authors
  1. E. V. Vasil’eva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. A. Abdullina
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. I. Kovalev
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. I. Kovalev.

Ethics declarations

Conflict of interests. The authors declare no conflict of interests.

Ethical approval. The experiments were organized in compliance with ethical standards controlling experiments on animals (European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes: EST no. 123 of March 18, 1986, Strasbourg; Good Laboratory Practice of the Health Ministry of the RF no. 199n of April 1, 2016). The experiments were approved by the Bioethics commission of the Zakusov Institute of Pharmacology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vasil’eva, E.V., Abdullina, A.A. & Kovalev, G.I. Subchronic Administration of Noopept and Semax Peptides Increases the Density of Cortical GABAA-Receptors in the Brain of BALB/c Mice. Neurochem. J. 15, 260–265 (2021). https://doi.org/10.1134/S1819712421030120

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1134/S1819712421030120

Keywords:

Search

Navigation